Campbell & CO Investment Adviser LLC Acquires New Shares in Inogen Inc (NASDAQ:INGN)

Campbell & CO Investment Adviser LLC acquired a new stake in shares of Inogen Inc (NASDAQ:INGN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,483 shares of the medical technology company’s stock, valued at approximately $311,000.

A number of other large investors also recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue acquired a new position in Inogen during the 3rd quarter valued at approximately $670,000. Ladenburg Thalmann Financial Services Inc. boosted its position in Inogen by 235.9% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,243 shares of the medical technology company’s stock valued at $283,000 after purchasing an additional 2,980 shares during the period. United Services Automobile Association boosted its position in Inogen by 1.8% during the 2nd quarter. United Services Automobile Association now owns 41,375 shares of the medical technology company’s stock valued at $2,762,000 after purchasing an additional 749 shares during the period. Voloridge Investment Management LLC boosted its position in Inogen by 16.4% during the 2nd quarter. Voloridge Investment Management LLC now owns 42,769 shares of the medical technology company’s stock valued at $2,855,000 after purchasing an additional 6,038 shares during the period. Finally, Nuveen Asset Management LLC acquired a new position in Inogen during the 2nd quarter valued at approximately $4,892,000.

In other news, Director Heath Lukatch acquired 2,000 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were bought at an average price of $43.01 per share, with a total value of $86,020.00. Following the purchase, the director now owns 5,481 shares of the company’s stock, valued at $235,737.81. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Loren L. Mcfarland acquired 1,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was purchased at an average cost of $42.93 per share, for a total transaction of $42,930.00. Following the purchase, the director now directly owns 4,481 shares in the company, valued at approximately $192,369.33. The disclosure for this purchase can be found here. Insiders own 4.54% of the company’s stock.

Shares of INGN stock opened at $48.98 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.82 and a current ratio of 7.35. Inogen Inc has a 1 year low of $41.19 and a 1 year high of $207.50. The stock has a fifty day moving average of $47.24 and a two-hundred day moving average of $62.58. The firm has a market capitalization of $1.07 billion, a PE ratio of 21.30, a price-to-earnings-growth ratio of 4.09 and a beta of 1.51.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Wednesday, August 7th. The medical technology company reported $0.45 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.50 by ($0.05). Inogen had a return on equity of 13.34% and a net margin of 11.24%. The business had revenue of $101.10 million for the quarter, compared to analyst estimates of $106.88 million. During the same quarter last year, the firm posted $0.65 EPS. The company’s revenue was up 3.9% compared to the same quarter last year. Equities research analysts predict that Inogen Inc will post 1.09 earnings per share for the current fiscal year.

A number of brokerages have issued reports on INGN. Svb Leerink reiterated a “market perform” rating and set a $47.00 price target (down previously from $78.00) on shares of Inogen in a research report on Thursday, August 8th. Needham & Company LLC lowered Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lowered Inogen from a “neutral” rating to an “underweight” rating and set a $72.00 price target for the company. in a research report on Wednesday, July 3rd. ValuEngine upgraded Inogen from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, BidaskClub lowered Inogen from a “sell” rating to a “strong sell” rating in a research report on Friday, August 9th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $82.17.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Article: Fiduciary

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.